New catheter coating could cut dialysis complications
NCT ID NCT07655544
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests a new dialysis catheter coated with Endexo technology, designed to resist blood clots and reduce infections. Researchers will compare its performance to older catheters in 50 adults with end-stage kidney disease. If successful, it could improve quality of life and lower healthcare costs for dialysis patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BioFlo Duramax catheter with Endexo technology
What this could lead to
If this works, it could mean fewer blocked catheters and infections for people on dialysis, making treatment smoother and safer.
What could go wrong
This is a small pilot study with only 50 people, comparing to past data rather than a direct head-to-head test. The new catheter may not perform better in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VASCULAR ACCESS COMPLICATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical University of Vienna
Vienna, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••